# A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients

> **NCT07197697** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy

## Key facts

- **NCT ID:** NCT07197697
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-10
- **Primary completion:** 2027-11-01
- **Final completion:** 2027-11-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07197697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07197697, "A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07197697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*